

# Provider Bulletin



## News and Information

Sept. 16, 2025

### Updated prior authorization criteria for drugs on the UCare Individual & Family Plans and UCare Individual & Family Plans with M Health Fairview formulary

On Nov. 1, 2025, prior authorization criteria for the drugs listed below will be updated. This change will be reflected in the [2025 Prior Authorization Criteria](#) forms.

Drug or category	Criteria change
PARP inhibitors for ovarian cancer: Zejula, Lynparza and Rubraca	Recently, Zejula (niraparib) had its FDA approval for first-line maintenance treatment of ovarian and related cancers narrowed. Previously, it was approved for any patient in a complete or partial response to their platinum-based chemotherapy; however, now it is limited to patients with a homologous recombination deficiency (HRD), which could be a BRCA mutation or other HRD genomic instability. This follows a narrowing of other PARP inhibitor products' indications over the last few years. Late-line treatment indications were voluntarily withdrawn by each manufacturer after final analysis of overall survival endpoints showed a detriment with the use of PARP inhibitors. Later, the maintenance treatment of recurrent disease was narrowed for each to only those patients with a BRCA mutation. Finally, both niraparib (Zejula) and olaparib (Lynparza) have had their first-line maintenance indication narrowed so that patients without HRD disease are no longer an FDA-approved population. In all trials, patients with a BRCA mutation have fared the best with PARP inhibitors, followed by slightly less robust responses for those with a different HRD, and then much more marginal benefits in patients without these types of genetic mutations. At this time, NCCN guidelines have also been narrowed to largely follow FDA approval. With niraparib being the final PARP inhibitor to have a narrowed first-line indication, we recommend a cleanup of criteria for ovarian cancer indications to align with the FDA indications for each of the PARP inhibitors and limit use to only those most likely to benefit. Additionally, there were some inconsistencies with phrasing and criteria across products, which will be aligned with this update, including Rubraca (rucaparib), which does not have a first-line maintenance indication.

[Pharmacy resources](#) are available on the UCare Provider website.